Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL-108 + Paclitaxel in Advanced Ovarian Cancer
NCT03078400Phase 1Unknown
- Sponsor
- Splash Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPL-108 in ovarian epithelial cancer (2 arms), sponsored by Splash Pharmaceuticals. Primary endpoint: Incidence of Adverse Events. Status: unknown.
02
Drugs
SPL-108
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT03078400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078400.